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INTRODUCTION
Fractures	are	indeed	a	vital	cause	of	death,	particular-
ly	in	aging	populations,	combined	with	cardiovascular	
and	respiratory	disorders.	The	repair	of	bone	fracture	
is	a	slow	and	complex	procedure	 that	 involves	a	 re-
generation	 of	 new	bone	 and	 absorption	 of	 old	 bone	
scaffolds.	 Surprisingly	 from	 the	 early	 stages	 of	 this	
process,	many	cell	types	are	involved	in	this	bone	re-
modeling	process.	From	the	early	callus	tissue	until	the	
healed	new	bone,	systemic	and	non-systemic	factors	
take	place	in	this	orchestra	of	bone	regeneration.	Dif-
ferentiation	 and	proliferation	of	many	 cellular	 types	
like	chondrocytes,	osteoblasts	e.t.c	are	influenced	by	
genetic	 background,	 systemic	 hormones,	 sensitivity	
to	mechanical	input,	drug	administration,	other	disor-
ders,	cytokines	and	many	more	factors.	Consequent-
ly	 fracture	 healing	 is	 declined	 by	 aging,	 so	 delayed	
union	of	fractures	is	most	common	in	elderly	patients	
(Figure	1).
Fractures	 are	 thoroughly	 classified	 according	 to	
the	 external	 force	 that	 induces	 the	 damage	 of	 bone	
continuity.	They	can	be	due	to	external	violence	and	
pressure	on	the	bone,	continuous	pressures	in	the	area,	
while	 a	 very	 unique	 form	 of	 fractures	 is	 caused	 by	
pathologic	 conditions	 such	 as	 osteoporosis.	Most	 of	
the	times	the	process	of	bone	healing	has	no	distinct	
phases.	In	the	early	stages	there	is	an	increased	blood	
supply	 causing	 a	 hematoma	 in	 the	 area	 of	 fracture.	
This	 is	 observed	 in	 experimental	models	 of	 rodents	
fracture	and	it	is	the	very	first	stage	of	bone	healing.	
Simultaneously	there	is	an	increased	surrounding	by	
macrophages	 and	 the	 broken	 ends	 become	 necrotic.	
Osteoclasts	then	remove	the	dead	bone	and	osteoblasts	
produce	new	bone,	parallel	with	fibroblasts	that	pro-
duce	fibrous	tissue	in	soft	tissue	injuries	of	the	area.	
Therefore	a	growing	firm	mass,	or	callus,	 is	created	
and	 that	 is	 the	early	beginning	of	ossification	of	 the	
osteoid.	Bone	remodeling	has	begun,	and	two	levels	
of	 growth	 callus	 are	 observed:	 subperiosteal	 callus	
that	forms	the	outside	of	injured	bone	and	endosteal	
callus.	The	pH	in	this	stage	is	increased	and	calcium	
hydroxapatite	crystals	are	deposited.	After	6	weeks	(in	
normal	conditions)	the	gaps	are	filled	and	bone	regains	
mechanical	strength,	but	only	after	1	year	does	bone	
remodeling	finish	with	normal	bone	microarchitecture	
to	be	restored1-6.
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Bone	gradually	gains	its	strength,	density	and	ar-
chitecture,	ideally	in	a	smooth	but	complicated	proce-
dure.	Unfortunately	the	stimuli	for	each	stage	are	still	
unknown	and	affected	by	several	external	and	 inter-
nal	factors.	At	the	end	bone	may	be	joined	by	a	mat	
of	 fibrous	 tissue	 or	 a	 false	 joint	 called	 pseudarthro-
sis.	Through	observations,	non-steroidal	anti-inflam-
matory	 drugs	 (NSAIDs)	 seem	 to	 have	 an	 inhibitory	
role	in	the	whole	bone	healing	process,	from	the	early	
stages	of	angiogenesis	in	bone	fracture	until	the	bone	
remodeling	 final	 stages.	 This	 review	 examines	 and	
analyzes	the	experimental	and	clinical	data	from	the	
use	of	NSAIDs	in	bone	fractures.
PHARMACOLOGY OF NON-STEROIDAL 
ANTI-INFLAMMATORY DRUGS
Back	 in	Hippocrates’	 times,	 the	cortex	of	Salix alba	
tree	was	used	for	its	antipyretic	property.	This	was	due	
to	the	large	quantities	of	salicylic	acid	in	the	cortex	of	
the	tree.	In	the	Roman	times	Celsius	used	an	extract	
of	Salix alba’s	leaves	as	analgesic.	Many	years	passed	
until	in	the	18th	century,	Edward	Stone	presented	the	
first	clinical	study	of	50	patients	cured	from	malaria’s	
fever	with	the	use	of	Salix alba’s	leaves.	In	1763,	he	
sent	his	results	in	a	letter	to	the	president	of	the	Royal	
Society	of	London.	From	that	point	scientists	tried	to	
isolate	and	produce	the	pure	substance	of	Salix alba’s	
leaves.	Leroux	 in	 1829	managed	 to	 isolate	 the	 pure	
form	of	salicylic	acid	and	proved	that	it	has	antipyret-
ic	properties.	Finally	in	1860	for	the	first	time	it	was	
synthetically	produced	in	Germany,	but	 it	was	taste-
less.	 After	 many	 unsuccessful	 tries,	 Bayer	 was	 the	
first	 pharmaceutical	 company	 that	 produced	 aspirin.	
Felix	Hoffman,	a	young	ambitious	chemist,	managed	
to	produce	aspirin	and	experiment	on	mouse	arthritis	
models.	For	the	very	first	time	the	name	aspirin	was	
given	by	Dresser	in	1899.	It	is	believed	that	the	name	
was	 taken	 by	 the	 name	 of	 the	 plant	 Spiraea,	 from	
which	aspirin	was	first	produced2,6,7.
In	1938	the	Lancet	journal	(see	study	from	Douth-
waite AH, Lindott GAM. Gastroscopic observation of 
the effect of aspirin in certain other substances in the 
stomach. Lancet 1938; 2:1222-1225)	published	on	the	
front	page	one	of	the	most	unwanted	effects	of	aspi-
rin	administration,	peptic	ulcers.	Then	a	new	group	of	
NSAIDs	was	developed	with	indomethacin	as	a	pro-
totype	but	it	had	the	same	unwanted	effects.	In	1971	
for	the	very	first	time,	after	long	research	by	Sir	John	
Vane,	 the	 scientific	 community	 realized	 the	mecha-
nism	of	action	of	NSAIDs.	Until	nowadays	NSAIDs	
are	the	number	one	on	the	list	of	prescribed	drugs	in	
the	USA	and	Europe	with	many	unwanted	effects2.7.
NSAIDs	 is	 a	 class	 of	 drugs	with	 anti-inflamma-
tory	 action,	 used	widely	 by	 physicians	 for	 its	 other	
two	properties:	 analgesic	 and	antipyretic.	According	
to	studies	NSAIDs	must	be	prescribed	only	if	there	is	
an	emergency	and	even	then	unwanted	effects	must	be	
considered.	The	main	unwanted	effects	involve	peptic	
ulcers,	 nausea,	 diarrhea,	 stomach	 ache,	 gastric	 tract	
Figure 1. Bone	healing	stages	are	not	always	distinct.	Bone	remodeling	process	is	an	established	model	regulated	
by	systemic	and	non-systemic	factors.
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bleeding,	 sensitivity	 reactions,	 cephalalgia.	 Aging	
population	is	a	group	of	high	risk	of	unwanted	effects,	
even	the	slightest	and	easy	going	effects	like	nausea,	
diarrhea	and	cephalalgia.	According	to	NICE,	people	
over	65	years	old	and	especially	women,	persons	with	
peptic	ulcers	in	the	past/present	or	consequences	of	it,	
are	 among	 the	high	 risk	group	 for	 unwanted	 effects	
from	administration	of	NSAIDs.	Additionally	careful	
attention	must	be	paid	 to	patients	 that	receive	medi-
cation	known	to	increase	the	severity	of	gastric	tract	
conditions	and	also	patients	with	long-term	intake	of	
NSAIDs.	 With	 any	 NSAID	 administration	 patients	
must	follow	a	gastric	protection	treatment	scheme.	In	
the	current	medical	bibliography	there	are	many	case	
reports	 and	 clinical	 studies	 of	 gastric	 bleeding	 and	
ulcers.	Many	 times	 these	 cases	 are	 accompanied	 by	
anaemia	and	hypoproteinaemia	symptoms7.
The	mechanisms	by	which	NSAIDs	cause	gastric	
ulcers	and	bleeding	are	under	investigation.	Proposed	
mechanisms	involve	inhibition	of	prostaglandins	syn-
thesis,	 reduction	 of	 immunity	 defenses,	 gastric	mu-
cosa	protection	and	production	of	cytokines.	Possibly	
there	 is	 a	 dysfunction	 of	 mitochondria	 in	 intestine	
cells	 resulting	 in	an	 increased	permeability	of	 intes-
tine	membrane	and	 invasion	of	bacteria.	 In	 the	 area	
of	injury,	neutrophils	concentrate	and	free	radicals	are	
produced.	 For	 this	 reason	 patients	 that	 take	 a	 small	
amount	 of	 aspirin	 for	 cardiovascular	 problems	must	
have	gastric	protection	medication,	for	example	a	pro-
ton	pump	inhibitor.	Gastric	protection	is	not	necessary	
for	young	patients.	 In	 extreme	cases,	 it	will	 be	use-
ful	to	have	a	microbial	test	for	the	presence	of	helico-
bacter	of	pylori	(H. pylori).	This	microorganism	may	
cause	gastric	ulcer	and	bleeding	according	to	several	
studies7-11.
NSAIDs	are	a	group	of	substances	that	inhibits	the	
enzyme	cyclooxygenase	(COX)	for	non-synthesis	of	
prostaglandins	 by	 arachidonic	 acid	 (Figure	 2).	 The	
arachidonic	 acid	 (cellular	 membrane	 phospholipids	
derivative)	 is	 synthesized	 by	 enzyme	 phospholipase	
A
2
.	So	NSAIDs	have	a	special	distinct	characteristic,	
they	selectively	inhibit	each	of	the	two	isoforms,	ei-
ther	COX-1	or	COX-2.	In	the	past	there	was	a	theory	
that	 the	 COX	 was	 a	 whole	 enzyme.	 Following	 re-
search	it	seems	that	there	are	two	isoforms	of	the	en-
zyme	and	probably	a	third	isoform.	COX-1	is	respon-
sible	for	the	production	of	prostaglandins	that	protect	
gastric	mucosa,	 induce	kidneys	and	platelets	normal	
function	 (production	 of	 thromboxane	 A
2
).	 COX-2	
involves	 the	 production	 of	 prostaglandins	 that	 take	
part	 in	 inflammatory	processes,	pain	and	renal	func-
tion	 (rennin	production).	Although	COX-2	 seems	 to	
be	a	sound	non-fatal	enzyme	to	be	inhibited,	the	use	
of	NSAIDs	COX-2	inhibitors	is	unwanted	in	patients	
Figure 2.	The	characteristic	pathways	of	prostaglandins	synthesis.	Non-steroidal	anti-inflammatory	drugs	inhibit	
both	the	isoforms	of	cyclooxygenase	enzyme.
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with	ischemic	cardiovascular	conditions	or	history	of	
heart	attacks.	So	physicians	must	prescribe	this	 type	
of	NSAIDs	for	small	term	therapies7,12-14.	It	seems	that	
COX-2	has	also	a	physiological	role.
In	normal	conditions,	COX-1	is	activated	in	all	tis-
sues	and	it	is	the	consistent	morph	of	COX	enzyme.	
COX-2	the	«inducible»	form	of	COX	is	expressed	in	
some	tissues.	The	«constitutive»	form	exists	in	central	
nervous	system,	kidneys,	 testicles	and	epithelium	of	
trachea.	Crystallographic	studies	in	the	two	isoforms	
showed	that	the	presence	of	each	form	of	enzyme	is	
due	to	few	morphologic	changes	in	the	structure.	The	
important	difference	is	in	the	active	centre	of	COX-2	
which	 is	 a	 little	bit	 larger	 and	has	a	 second	 internal	
junction	position	for	heavier	substances	in	molecular	
weight.	 Therefore	 selective	 NSAIDs	 with	 different	
molecular	weights	may	 be	 conjugated	 time-depend-
ently	and	non-reversibly	with	COX-1	or	COX-2.	Big	
molecular	 weight	 non-selective	 NSAIDs	 are	 conju-
gated	with	both	the	two	isoforms	of	COX	enzyme	in	
instantly	reversible	way7,12-14.
NSAIDs	 have	 three	 distinct	 features:	 analgesic,	
antipyretic	 and	 anti-inflammatory.	 The	 most	 impor-
tant	NSAIDs	are	shown	on	Table	I.	 In	 the	family	of	
propionic	acid,	the	prototype	drug	is	ibuprofen.	It	was	
the	first	drug	commercialized	in	USA	and	then	it	was	
followed	by	naproxen,	fenoprofen,	ketoprofen,	flurbi-
profen	and	last	oxaprozin.	Another	family	is	indolonic	
acids	(indomethacin,	sulindac	and	etodolac).	Oxicam	
derivatives	were	used	extensively	when	released,	be-
fore	 their	use	was	 stopped	because	of	 the	unwanted	
effects.	 Meloxicam	 is	 the	 latest	 that	 had	 fewer	 un-
wanted	 effects.	 Phenylbutazon	 is	 a	 pyrazol	 product	
with	anti-inflammatory	action	but	weak	analgesic	and	
antipyretic	properties.	Diclofenac,	ketorolac,	tolmen-
tin	 and	nabumetone	 are	good	 analgesic	 agents.	Last	
but	not	least	coxib	family	with	celecoxib,	rofecoxib,	
eterocoxib	is	used	under	supervision	for	their	side	ef-
fects	in	cardiovascular	and	gastric	system5,6,8,15-17.
Just	like	all	agents,	NSAIDs	have	interactions	with	
other	drugs	shown	on	Table	II.
IN THE QUEST FOR THE ANSWER
Animal	 studies	 are	 directed	 to	 one	 preferable	 con-
clusion:	 Conventional	 non-specific	 NSAIDs	 delay	
healing	 in	 complete	 fractures.	The	 best	 documented	
substances	 were	 indomethacin,	 diclofenac,	 naprox-
en,	 ketorolac,	 ibuprofen	 and	 naproxen.	These	 drugs	
caused	slower	fracture	healing	in	early	stages2,14,18-22.	
Fractures	may	 vary	 including	 rat	 forelimb,	 vertebra	
or	 femur.	Notice	 that	 the	 doses	 of	NSAIDs	 used	 in	
animal	fracture	models	that	show	an	obvious	delayed	
bone	union	(according	to	histological,	radiological	and	
biochemical	testings),	are	larger	than	the	typical	doses	
of	administration	in	humans35.	Many	substances	must	
reach	 toxicity	 levels	 in	 experimental	 animal	models	
so	as	to	have	fracture	delayed	union.	A	possible	cause	
of	 this	fact,	 that	 is	 less	known	by	the	researchers,	 is	
that	COX	inhibitors	are	metabolized	very	quickly	by	
hepatic	enzymes	(first	 route	of	metabolism),	so	 they	
present	 low	 final	 serum	 concentrations	 relevant	 to	
bone	healing	fracture6,8,23.
Indomethacin	followed	by	ketorolac	both	appeared	
to	have	an	 important	 inhibitory	action	 in	bone	heal-
ing	process.	Experimental	models	indicate	that	there	
is	poor	mineralization	of	demineralized	bone	matrix	
grafts	and	Harvesian	remodeling.	These	agents	delay	
bone	union	process	but	they	do	not	inhibit	it2,8,14,24,32.	
Studies	 in	knockout	mice	 (COX-1	and	COX-2	null)	
have	very	 impressive	 results.	COX-2-/-	mice’s	 endo-
chondral	 ossification	 was	 delayed	 compared	 with	
COX-1	knockout	mice.	It	seems	that	COX-2	selective	
inhibitors	 delay	 bone	 formation	 more	 than	 COX-1	
inhibitors.	 In	Saos-2	osteoprogenitor	cell	 lines,	after	
treatment	with	celecoxib,	a	selective	COX-2	inhibitor,	
there	was	a	decrease	in	osteogenesis	potential.	It	seems	
that	COX-2	inhibitors	like	celecoxib	and	rofecoxib	in-
hibit	bone	regeneration.	The	question	is	in	what	phase	
do	NSAIDs	inhibit	bone	formation?2,19,25-28
It	is	believed	that	COX	inhibitors	act	in	the	process-
es	downstream	of	the	initial	inflammatory	response	at	
fracture	sites.	By	using	knockout	COX-2	mice	Zhang	
et	al.	showed	that	there	was	a	reduction	in	expression	
levels	 of	 bone	morphogenetic	 protein	 -	 2	 (BMP-2),	
osteogenic	 differentiation	 transcription	 core	 binding	
factor	(cbf-α1)	and	osterix.	BMP-2	is	a	powerful	os-
teoblastic	growth	factor,	expressed	in	the	early	stages	
of	bone	union.	It	is	a	member	of	TGF-β	superfamily,	
crucial	for	bone	formation.	One	proposed	mechanism	
indicates	the	inhibition	caused	by	COX	inhibitors	of	
the	expression	of	growth	factors	such	as	interleukine	
-1,-6	(IL-1,-6),	tumor	necrosis	factor	-	α	(TNF-α)	and	
others.	It	is	known	that	these	factors	play	vital	role	in	
the	initiation	of	inflammatory	processes	and	vasculo-
	 In	the	Quest	for	the	Etiology	of	the	Delayed	Union	of	Fractures:	The	Inhibitory	Role	of	Non-steroidal Anti-inflammatory	Drugs 29
Table 1. Major	groups	of	non-steroidal	
anti-inflammatory	drugs34,35.
Propionic	acid	derivatives	family
Indolonic	acid	derivatives	family
Oxicam	derivatives	family
Phenylbutazon
Diclofenac,	ketorolac,	tolmetin	and	nabumetone	family
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genic	 proliferation	 at	 the	 early	 stages	 of	 bone	 heal-
ing14,25-29.	Another	mechanism	that	may	involve	COX-
2	and	bone	 repair	 indicates	 that	COX-2	maintains	a	
population	 of	mesenchymal	 stem	 cells	 in	 pre-osteo-
blast	state,	so	during	injury	cases	like	bone	fractures,	
COX-2	may	 affect	 through	 regulation	 of	 cbfa1	 and	
osterix	 in	 an	 upstream	 of	 reactions	 with	 osteoblast	
differentiation	 to	 mature	 osteocytes.	 COX-2	 inhibi-
tors	delay	this	procedure	by	reducing	BMP-2	levels	as	
previously	reported21.
In	clinical	 level,	NSAID	seems	to	 inhibit	hetero-
topic	 bone	 formation	 after	 hip	 arthroplasty,	 accord-
ing	 to	 several	 studies.	This	 is	 an	advantage	 in	 these	
situations,	but	brings	us	in	front	of	a	debate	whether	
NSAIDs	 inhibit	 fracture	 healing.	Nevertheless	 there	
is	not	yet	a	defined	answer	whether	NSAIDs	 inhibit	
bone	healing	process.	Risk	factors	that	adversely	may	
inhibit	 fracture	 healing	 include	 smoking,	 diabetes	
mellitus,	peripheral	arterial	occlusive	disease	and	oth-
ers30,31.	Some	 researchers	believe	 that	administration	
of	NSAIDs	in	 late	phase	of	fracture	healing	is	asso-
ciated	with	 non-union	 cases18,30.	Most	 studies	 found	
no	significant	differences	 in	 fracture	 risk	and	use	of	
NSAIDs30-32.	Despite	 the	 fact	 that	most	 cases	 found	
no	association	between	NSAIDs	and	bone	mal-union,	
there	is	a	lack	of	evidence	in	these	studies.	No	clini-
cal	trials	are	accomplished	with	specific	protocols	of	
exclusion	of	NSAIDs	use	in	other	treatments.	Notice	
that	NSAIDs	are	widely	used	in	 today	clinical	prac-
tice	for	musculoskeletal	conditions.	Most	of	the	stud-
ies	were	retrospective	and	not	randomized-controlled	
trials	with	lack	of	methodology.	This	is	an	issue	of	an	
Orthopaedics	clinic	whether	or	not	to	use	NSAIDs	in	
post-operation	 pain	 and	 inflammation.	 Scientifically	
Coxib	family
Table 2. Important	drug	reactions	with	non-steroidal	anti-inflammatory	drugs34,35.
Aminoglycosides
Anticoagulants
Antihypertensitives	(α-blockers,	β-blockers,	diuret-
ics,	 angiotensin	 II	 receptor	 blockers,	 angiotensin-
converting	enzyme		inhibitors)
Corticosteroids
Lithium
Cyclosporine
Methotrexate
Reduction	of	clearance	levels	of	aminoglycosides	through	
kidney		with		induced	toxicity.
Hypoprothrombithemia,	 low	 platelet	 concentration	 with	
high	risk	of	gastric	bleeding.
With	 the	co-administration	of	NSAIDs	 there	 is	an	 inhibi-
tion		of	antihypertensitives	action,	ion	and	water	retention	
by	pyrazole	derivatives.
Increased	risk	for	peptic	ulcer	.
Decreased	clearance	of	lithium	through	kidneys.
Increased	nephrotoxicity.
Decreased	 clearance	 of	 methotrexate	 in	 kidney	 and	 in-
creased		levels	of	methotrexate	in	serum	-	toxicity.
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established	results	come	only	from	animal	studies	so	
there	is	a	need	for	more	studies	in	clinical	level.
NEW TRENDS IN THE AREA OF NSAIDS  
AND FRACTURE NON-UNION
In	the	search	for	the	answer	to	this	major	problem,	we	
must	consider	that	mal-union	of	fractures	is	not	just	a	
topic	of	NSAIDs	administration.	Genetic	background	
of	patients	is	an	important	factor	of	non-union	and	its	
key	 role	 should	be	 considered.	Despite	 the	 fact	 that	
there	 is	no	clear	evidence	for	 the	use	of	NSAIDs	 in	
post-surgical	pain	and	inflammation	during	orthopae-
dic	operation,	NSAIDs	are	widely	used	for	these	pur-
poses.	There	is	need	for	more	research	in	both	experi-
mental	and	clinical	level	for	the	safe	use	of	NSAIDs	in	
bone	fracture.	There	is	a	precautionary	sense	about	the	
use	of	NSAIDs	because	of	their	inhibitory	role	in	bone	
fracture,	 therefore	 orthopaedists	 must	 be	 very	 care-
ful	in	the	use	of	NSAIDs	in	these	cases.	Maybe	new	
technologies	must	 be	 innovated	 so	 as	 to	 implement	
NSAIDs	in	topical	form	by	using	nanomolecules33.
ΠΕΡΙΛΗΨΗ:	Η	καθυστερημένη	πώρωση	του	κατάγματος	αποτελεί	σημαντικό	πρόβλημα	στην	Ορθοπαιδική.	Στην	ανα-
σκόπηση	αυτή	προσεγγίζεται	ο	ρόλος	των	μη	στεροειδών	αντιφλεγμονωδών	φαρμάκων	(ΜΣΑΦ)	στην	πώρωση	των	καταγ-
μάτων.	Σύμφωνα	με	εργαστηριακές	μελέτες,	τα	ΜΣΑΦ	αναστέλλουν	την	πώρωση	των	καταγμάτων	στα	πρώτα	στάδια	της	
διαδικασίας.	Εντούτοις	ελάχιστες	είναι	οι	κλινικές	μελέτες	που	έχουν	γίνει	μέχρι	σήμερα.	Οι	περισσότερες	δεν	παρέχουν	
σαφή	απάντηση	ως	προς	την	ανασταλτική	δράση	των	ουσιών	αυτών.	Οι	αναστολείς	COX-2	φαίνεται	ότι	ασκούν	παρόμοια	
δράση	με	τα	κλασικά	ΜΣΑΦ.	Παρ’	όλες	τις	ανεπιθύμητες	ενέργειές	τους	στο	γαστρεντερικό,	καρδιαγγειακό	σύστημα	και	
στην	πώρωση	του	κατάγματος,	χρησιμοποιούνται	ευρέως	στον	μετεγχειρητικό	πόνο	μετά	από	ορθοπαιδικές	επεμβάσεις	και	
σε	φλεγμονώδεις	καταστάσεις.
Λέξεις Κλειδιά: Μη στεροειδή αντιφλεγμονώδη φάρμακα, Πώρωση καταγμάτων, Κοξίμπες, ψευδάρθρωση.
Aναζητώντας την αιτιοπαθογένεια καθυστερημένης πώρωσης των καταγμάτων.  
Ο ανασταλτικός ρόλος των μη στεροειδών αντιφλεγμονωδών φαρμάκων  
είναι ένα σύνθετο φαρμακολογικό φαινόμενο;
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